PT-141 (Bremelanotide) for Women: Libido, Safety, and What to Know
PT-141 / Vyleesi is FDA-approved for low sexual desire in premenopausal women. Here's how it works, what the research shows, and what to know about safety.
By Anthivera Editorial · Updated · 1 min read
Awaiting medical reviewDraft
Status: Stub. Outline is in place per
/docs/CONTENT-PLAN.md(Article 3).
What PT-141 / Vyleesi is#
Section content TBD. The key fact: FDA-approved for HSDD in premenopausal women.
How it works#
Section content TBD. Melanocortin receptor activation in the brain (not a hormone, not a vascular drug).
What the Phase 3 trials showed#
Section content TBD. Be measured about effect size.
Premenopausal vs. postmenopausal use#
Section content TBD. The approved population matters; postmenopausal use is off-label.
Safety profile and side effects#
Section content TBD. Nausea, flushing, contraindications, who it's not for.
How women access PT-141#
Section content TBD. Prescription required; telehealth pathways.
PT-141 vs. other approaches to low desire#
Section content TBD. Where it fits among the other options.